2 results
Approved WMOWill not start
In a small pilot study to investigate possible occurence of blood chemistry deviations and / or a tamponade after the application of ACF-Matrix haemostat in the (L)IMA bed.
Approved WMOCompleted
1. Overall survival (primary efficacy endpoint)2a. Efficacy: progression-free survival (PFS), overall response rate (ORR = CR + PR), and a clincal benefit rate (CBR) will be evaluated as CR + PR + SD for at least 3 months.2b. Safety: adverse events…